模拟动态治疗策略的靶试验:STAR*D 数据中重度抑郁症的管理比较
本研究基于 STAR*D 试验中 1436 例西酞普兰治疗失败且仍需抗抑郁治疗的患者,设计并模拟了一个靶试验,比较序贯单药治疗、序贯双药非选择性 5-羟色胺再摄取抑制剂治疗(SD)和基于指南的策略。主要结局为症状缓解,次要结局为严重事件。结果显示基于指南的策略与更高的缓解概率和更低的严重不良事件风险相关。
要点
- 基于指南的策略 9 个月缓解概率为 53.2%,序贯单药组为 43.5%。
- 与序贯单药组相比,基于指南策略的缓解相对风险为 1.22(0.96–1.46)。
- 基于指南策略的严重事件 9 个月相对风险为 0.62(0.33–1.00)。
核心结论
- 基于指南的策略与缓解概率增加及严重不良事件风险降低相关。
研究设计与样本
- 在 STAR*D 试验中识别 1436 例西酞普兰治疗失败且仍需抗抑郁治疗的患者,设计并模拟靶试验,最终 971 例符合模拟条件。
- 使用逆概率加权控制潜在混杂。
主要发现
- 9 个月缓解概率:序贯单药组 43.5%,SD 组 47.6%,基于指南策略组 53.2%。
- 与序贯单药组相比,9 个月缓解概率差异:SD 组 -4.2%(95%CI -15.6 至 4.6),基于指南策略组 -9.7%(-19.3 至 1.9)。
- 9 个月缓解相对风险:SD 组 1.09(0.90 至 1.38),基于指南策略组 1.22(0.96 至 1.46)。
- 9 个月严重事件相对风险:SD 组 0.77(0.38 至 1.40),基于指南策略组 0.62(0.33 至 1.00)。
- 敏感性分析结果一致。
关键数值与推荐
- 缓解定义为汉密尔顿抑郁量表评分≤7 或 16 项快速抑郁症状学量表-临床评定连续两次评分≤5。
- 严重事件包括住院、自杀和死亡。
临床怎么用
- 对于西酞普兰治疗失败且仍需抗抑郁治疗的患者,采用基于指南的策略(部分反应加用第二种药物,无反应或不耐受则换药)可能提高缓解概率并降低严重事件风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical guidelines recommend adding a second drug for patients with major depressive disorder who have a partial response and switching antidepressants for those who show no response or intolerance. This guidelines-based strategy was compared with other strategies for the management of unresponsive depression. METHODS: A total of 1436 individuals experiencing treatment failure with citalopram and still requiring antidepressant therapy were identified in the STAR∗D (Sequenced Treatment Alternatives to Relieve Depression) trial. A (hypothetical) target trial was then designed and emulated. The following strategies for decision making were compared: sequential monotherapy, sequential dual non-selective serotonin reuptake inhibitor therapy (SD), and a guidelines-based strategy. The primary outcome was symptomatic remission defined as a Hamilton Depression Rating Scale score ≤7 or 2 consecutive scores ≤5 on the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated. Secondary outcomes were serious events (hospitalizations, suicide, and mortality). Inverse probability weighting was used to control for possible confounding. RESULTS: A total of 971 patients were eligible for our emulation. Patients initiating SD had the lowest levels of depression at baseline. The estimated 9-month probability of remission was 43.5% for the sequential monotherapy group, 47.6% for the SD group, and 53.2% for the guidelines-based strategy group. Compared with the sequential monotherapy group, the difference in 9-month probability of remission was -4.2% (95% CI, -15.6 to 4.6) for the SD group and -9.7% (-19.3 to 1.9) for the guidelines-based strategy group. The 9-month relative risks of remission were 1.09 (0.90 to 1.38) and 1.22 (0.96 to 1.46), respectively. Results were consistent across sensitivity analyses. The 9-month relative risks of serious events were 0.77 (0.38 to 1.40) and 0.62 (0.33 to 1.00), respectively. CONCLUSIONS: Using the guidelines-based strategy was associated with an increased probability of remission and a lower risk of serious adverse events. The potential implications are substantial given the large number of patients experiencing treatment failure to antidepressants.
引用
- Szmulewicz AG, Wanis KN, Perlis RH, et al. Emulating a Target Trial of Dynamic Treatment Strategies for Major Depressive Disorder Using Data From the STAR∗D Randomized Trial. Biol Psychiatry. 2022. PMID: 36639294. doi:10.1016/j.biopsych.2022.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。